Clinical Trial

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Study acronym: MM09-SIT-023
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-06-15; most recent amendment 2025-05-07.
Status change: Not Yet Recruiting → Recruiting 2020-10-29
Trial Details
NCT Number NCT04435990
Lead Sponsor Inmunotek S.L.
Collaborators: BioClever 2005 S.L.
Conditions Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
Enrollment 150 participants
Start Date 2020-10-06
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-13